SCHEMBL6850798

SCHEMBL6850798

OCC#Cc1ccc(B(O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 4/20 0.50
MMP2 P08253 1/20 0.44
MMP12 P39900 1/20 0.44
LPL P06858 3/20 0.40
LIPG Q9Y5X9 3/20 0.40
MELK Q14680 1/20 0.40
CA2 P00918 3/20 0.39
CA1 P00915 2/20 0.39
TSHR P16473 1/20 0.39
F11 P03951 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6850616 0.83 ENPP2 (0.47) ENPP2LPLLIPGCA2CA1
SCHEMBL6446069 0.83 MMP2 (0.55) MMP2MMP12MELKHRH3GABRP
SCHEMBL806832 0.81 ENPP2 (0.64) ENPP2LPLLIPGCA2CA1
SCHEMBL806833 0.81 ENPP2 (0.64) ENPP2LPLLIPGCA2CA1
SCHEMBL6851939 0.80 GABRP (0.44) ENPP2MMP2MMP12LPLLIPG
SCHEMBL9161829 0.78 LPL (0.47) ENPP2MMP2MMP12LPLLIPG
SCHEMBL9672111 0.77 MMP2 (0.50) MMP2MMP12MELKHRH3GABRP
SCHEMBL806834 0.77 ENPP2 (0.58) ENPP2LPLLIPGCA2CA1
SCHEMBL27175666 0.76 ENPP2 (0.53) ENPP2LPLLIPGCA2CA1
SCHEMBL11214760 0.75 APP (0.50) MMP2MMP12MELKCA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825170-B2 ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-11-30 US disclosed
EP-1453847-A1 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS Ortho-Mcneil Pharmaceutical, Inc. (US) 2004-09-08 EP disclosed
US-20030220272-A1 6-O-acyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-11-27 US disclosed
WO-2003050132-A1 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220272-A1 6-O-acyl ketolide antibacterials Q6ZSR9, ACSL6, RPS4Y1 ENPP2 1524/4885MMP2 1924/4885MMP12 1503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.